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SBI-0206965, originally identified as an inhibitor of the autophagy initiator kinase ULK1,
has recently been reported as a more potent and selective AMP-activated protein kinase
(AMPK) inhibitor relative to the widely used, but promiscuous inhibitor Compound C/
Dorsomorphin. Here, we studied the effects of SBI-0206965 on AMPK signalling and
metabolic readouts in multiple cell types, including hepatocytes, skeletal muscle cells
and adipocytes. We observed SBI-0206965 dose dependently attenuated AMPK activator
(991)-stimulated ACC phosphorylation and inhibition of lipogenesis in hepatocytes. SBI-
0206965 (≥25 μM) modestly inhibited AMPK signalling in C2C12 myotubes, but also
inhibited insulin signalling, insulin-mediated/AMPK-independent glucose uptake, and
AICA-riboside uptake. We performed an extended screen of SBI-0206965 against a panel
of 140 human protein kinases in vitro, which showed SBI-0206965 inhibits several
kinases, including members of AMPK-related kinases (NUAK1, MARK3/4), equally or
more potently than AMPK or ULK1. This screen, together with molecular modelling,
revealed that most SBI-0206965-sensitive kinases contain a large gatekeeper residue
with a preference for methionine at this position. We observed that mutation of the gate-
keeper methionine to a smaller side chain amino acid (threonine) rendered AMPK and
ULK1 resistant to SBI-0206965 inhibition. These results demonstrate that although SBI-
0206965 has utility for delineating AMPK or ULK1 signalling and cellular functions, the
compound potently inhibits several other kinases and critical cellular functions such as
glucose and nucleoside uptake. Our study demonstrates a role for the gatekeeper
residue as a determinant of the inhibitor sensitivity and inhibitor-resistant mutant forms
could be exploited as potential controls to probe specific cellular effects of SBI-0206965.
Introduction
AMP-activated protein kinase (AMPK) is an important regulator of energy balance [1,2]. AMPK has
long held promise as a therapeutic target for metabolic syndrome, as its activation in multiple meta-
bolic tissues resulted in amelioration of insulin resistance and reduction in hyperglycemia in preclin-
ical studies [3–5]. For example, active AMPK inhibits fatty acid biosynthesis in the liver through
phosphorylation and inactivation of acetyl-CoA carboxylase-1 (ACC1) [6,7]. The activation of AMPK
also leads to increased fatty acid oxidation through phosphorylation of ACC2 [8], and glucose uptake
in skeletal muscle, at least in part through phosphorylation of TBC1D1 [9,10], a Rab
GTPase-activating protein (GAP) which modulates trafficking of GLUT4-containing vesicles [11].
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Each exists as multiple isoforms (α1/α2, β1/β2, γ1/γ2/γ3), generating up to 12 possible combinations [2].
AMPK is activated through phosphorylation of threonine 172 (Thr172) within the activation segment of the α
subunit kinase domain [12]. The major upstream kinases phosphorylating Thr172 are liver kinase B (LKB1)
and Ca2+- calmodulin-dependent protein kinase kinase-2 (CaMKK2) [2]. The γ-subunits contain four tandem
cystathionine β-synthase (CBS) motifs that bind adenine nucleotides. The binding of ADP and/or AMP to CBS
motifs causes conformational changes that increase net Thr172 phosphorylation [13–15]. In addition, the
binding of AMP, but not ADP, further increases AMPK activity through allosteric stimulation [13]. AMPK
activity is, therefore, regulated in a multi-layered process, often involving a combination of posttranslational
modifications and allosteric regulation [16].
To delineate cellular and physiological roles for AMPK, small-molecule activators have played important
roles. The most widely used small-molecule activator of AMPK is 5-aminoimidazole-4-carboxamide riboside
(AICAR), a prodrug of AMP-mimetic ZMP, which was used for probing the AMPK-dependent (and
insulin-independent) stimulation of glucose uptake in skeletal muscle [17–19]. However, the specificity of
AICAR has been challenged and numerous AMPK-independent actions of AICAR have been reported [20–23].
Specific allosteric activators and new mechanisms for their targeting of AMPK have recently been discovered.
The crystallographic structures of AMPK trimeric complexes revealed that A-769662 (a member of the thieno-
pyridone family [24]) and 991 (a benzimidazole derivative, also known as ex229) bind in an allosteric drug
and metabolite (ADaM) pocket located at the interface of the α subunit (kinase domain N-lobe) and β subunit
(carbohydrate-binding module) [25,26]. We and others have shown that 991, and its two related analogues
with improved bioavailability (MK-8722, PF-739), are potent and highly specific AMPK activators [4,5,21,27].
Collectively, these activators and their analogues are exploited for drug development (e.g. for metabolic disor-
ders) and have also been used extensively as research tools to delineate AMPK’s molecular and physiological
roles in cellular and organismal contexts [3].
In contrast, the availability of small-molecule AMPK inhibitors as research tools is vastly limited. The most
widely utilised AMPK inhibitor, the pyrazolopyrimidine derivative Compound C (also known as
Dorsomorphin), was originally discovered in a high-throughput screen and used to probe AMPK-dependent
metabolic actions of metformin in hepatocytes [28]. Compound C is an ATP-competitive inhibitor and binds
to the highly conserved active site of the AMPKα catalytic domain [29]. However, Compound C/
Dorsomorphin inhibits several other kinases in vitro with similar or much greater potency than AMPK [30–32]
and elicits numerous AMPK-independent biological effects [33].
SBI-0206965, a 2-aminopyrimidine derivative, was originally identified through screening a library of pyrimi-
dine analogues as an ATP-competitive inhibitor of the autophagy initiator kinase ULK1, with the ability to
inhibit ULK signalling and ULK1-mediated survival of lung cancer and glioblastoma cells when coupled with
nutrient stress [34]. Interestingly, using cell-free phosphorylation of the AMPK and the ULK1 synthetic peptide
substrate S108tide as a measure of kinase activity [35], it was recently reported that SBI-0206965 (used at
1 μM) was a more effective inhibitor of AMPK (80% inhibition) compared with ULK1 (63% inhibition) [32].
In addition, SBI-0206965 has demonstrated much higher potency and selectivity toward AMPK when directly
compared with Compound C in cell-free assays, even though several other kinases (including JAK3, Src, FAK,
Abl, Aurora A/B) were also selectively inhibited [32,34,36,37]. Mechanistically, a co-crystal structure of the
AMPKα2 kinase domain-SBI-0206965 complex showed that the drug occupies a pocket that partially overlaps
with the ATP-binding site; however, SBI-0206965 displayed mixed-competitive kinetics [32]. SBI-0206965 inhi-
bits glucose deprivation-, AICAR-, A769662- or ionomycin-induced cellular AMPK activation, judged by phos-
phorylation of AMPK substrates, at doses ranging from 5 to 30 μM in multiple cell lines including HEK293,
SH-SY5Y, mouse embryonic fibroblasts, or HUVECs [32,38,39] with no associated metabolic readouts of
AMPK assessed.
In the current study, we initially sought to evaluate the effects of SBI-0206965 on AMPK signalling and
metabolic readouts in multiple cell types, including hepatocytes, skeletal muscle cells, and adipocytes. We
observed SBI-0206965 dose dependently attenuated AMPK-dependent stimulation of ACC phosphorylation
and inhibition of lipogenesis with the direct AMPK activator 991 in mouse primary hepatocytes. SBI-0206965
(≥25 μM) only modestly inhibited AMPK signalling in C2C12 myotubes and adipocytes, but potently inhibited
basal and AMPK-independent (or insulin-stimulated) glucose transport and nucleoside uptake. We next per-
formed an extended (activity-based) screen of SBI-0206965 using a panel of 140 human protein kinases in vitro
to test our hypothesis that SBI-0206965 would inhibit AMPK-related kinases, given the structural similarities of
the kinase domains of AMPK and AMPK-related kinases [40,41]. This screen, together with molecular
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modelling and structure-guided mutagenesis, has identified that SBI-0206965 inhibits several kinases with equal
or higher potency, including the AMPK-related kinases NUAK1, MARK3 and MARK4.
Materials and methods
Materials
5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR, #OR1170T) was obtained from Apollo Scientific.
991 (#AOB8150) was purchased from Aobious. Insulin (#I9287) and SBI-0206965 (#SML1540) were obtained
from MerckMilliporeSigma. A769662 (#3336) and S-(4-Nitrobenzyl)-6-thioinosine (NBMPR, #2924) were
purchased from Tocris Bioscience. Deoxy-D-[1, 2-3H]-glucose, [5, 6-3H]-uridine, [1-14C]-Acetic acid and
[U-14C]-D-glucose were purchased from PerkinElmer. Rotenone (#R8875) was obtained from
MerckMilliporeSigma. Cell culture reagents were purchased from Thermo Fisher Scientific. All other materials,
unless otherwise indicated, were from MerckMilliporeSigma.
Antibodies
AS160 (#07-741), Flag (#F7425), α-tubulin (#T6074), and phospho-TBC1D1 Ser237 (#07-2268) antibodies
were purchased from MerckMilliporeSigma. ACC (#3676), phospho-ACC1 Ser79 (#3661), Akt (#4691),
phospho-Akt Ser473 (#4060), phospho-Akt Thr308 (#9275) AMPKα (#2532), phospho-AMPKα Thr172
(#2535), phospho-AS160 Thr649 (#8881), ERK1/2 (#4695), phospho-ERK1/2 Thr202/Tyr204 (#4370), GSK3β
(#9315), phospho-GSK3β Ser9 (#9322), HSP90 (#4874), p70S6K1 (#2708), phospho-p70S6K1 Thr389 (#9234),
Raptor (#2280), phospho-Raptor Ser792 (#2083), TBC1D1 (#4629), ULK1 (#8054), phospho-ULK1 Ser555
(#5869), and vinculin (#13901) antibodies were purchased from Cell Signaling Technology.
Experimental animals
Animal experiments were performed in accordance with the European directive 2010/63/EU of the European
Parliament and of the Council of the protection of animals used for scientific purposes. Ethical approval was
given by the Danish Animal Experiments Inspectorate (#2015-15-0201-00796) or by the Regional Ethical
Committee on Animal Experiments in Malmö/Lund (#5.8.18-18569/2018). Animal studies were conducted on
C57BL/6NTac male mice (obtained from Taconic Biosciences) at 9–12 weeks of age in the animal facility at the
Faculty of Health and Medical Sciences (University of Copenhagen) or 36- to 38-day-old Sprague-Dawley rats
(obtained from Taconic Biosciences) in the animal facility at the Biomedical Centre (Lund University, Sweden).
Animals were maintained on a standard chow diet and 12 : 12-h light–dark cycle.
Mouse primary hepatocytes isolation, culture, and lipogenesis assay
Mice were anesthetised via intraperitoneal injection of avertin, prepared from a stock of 1 g/ml tribromoethanol
(#T48402, MerckMilliporeSigma) in 2-methyl-2-butanol (#152463, MerckMilliporeSigma), diluted 1 : 20 in
saline, and dosed as 10 μl/g body weight. Hepatocytes were isolated by collagenase perfusion as previously
described [42,43]. Hepatocytes were seeded in medium Eagle-199 (MEM-199) (#41150, Thermo Fisher
Scientific) containing 100 U/ml penicillin G, 100 μg/ml streptomycin and 10% (vol/vol) FBS. Hepatocytes were
left for attachment (3–4 h) and cultured overnight at 37°C with 5% CO2 in MEM-199 supplemented with
100 U/ml penicillin G, 100 μg/ml streptomycin, 10 nM insulin, and 100 nM dexamethasone. Twenty-four
hours after seeding, primary hepatocytes were incubated for 1 h for signalling studies as described [42] or 3 h
with MEM-199 supplemented with 0.6 μCi/ml [14C]-acetate in the presence of SBI-0206965 with 991 or vehicle
(0.1% DMSO). Cells were harvested in 0.5 ml PBS, transferred into 1 ml 40% KOH and 2 ml methanol followed
by 1 h incubation at 80°C. Lipids were saponified by acidifying the samples in 37% HCl and extracted with pet-
roleum ether. Extracts were allowed to evaporate to dryness, then dissolved in Ultima Gold scintillation fluid
for determination of [14C]-acetate incorporation into lipids.
C2C12 skeletal muscle cell culture, treatment, and glucose uptake
measurement
C2C12 (#CRL-1772, ATCC) myoblasts were cultured and differentiated into myotubes as described [44]. Fully
differentiated C2C12 myotubes (day 4–5) were serum starved in DMEM for 4 h followed by 1 h incubation
with bicarbonate-free media (DMEM, 20 mM HEPES, 0.2% BSA, pH 7.4). Cells were then pre-incubated in
Krebs-Ringer HEPES (KRH) buffer (140 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.25 mM MgSO4, 10 mM
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HEPES, 1.2 mM KH2PO4, and 0.2% BSA) with vehicle (0.1% DMSO) or SBI-0206965 for 30 min followed by
an additional 1 h incubation with 991 (10 μM) or insulin (100 nM). Cells were incubated in KRH buffer con-
taining 50 μM [3H]2-deoxyglucose (0.1 μCi/ml) for 5 min and the reaction was stopped by adding 25 mM
glucose. The cells were washed in KRH buffer and harvested in ice-cold lysis buffer. Two-third of the lysate was
used for immunoblot analysis and the remaining one-third was analysed by scintillation counting to measure 2-
deoxyglucose uptake in the cells.
Ex vivo mouse skeletal muscle incubation
Mice were anesthetised by avertin (as described above) via intraperitoneal injection, and extensor digitorum
longus (EDL) muscle was rapidly dissected and mounted in oxygenated (95% O2 and 5% CO2) and warmed
(30°C) Krebs-Ringer buffer in a myograph system (820MS, Danish Myo Technology) as described [27,45]. The
muscles were incubated in the presence of the indicated compounds or vehicle (0.1% DMSO) for 50 min
before snap-frozen in liquid nitrogen.
Rat primary adipocyte isolation, culture, treatment, and glucose uptake
assay
Adipocytes were isolated by collagenase digestion as described [46]. After isolation, primary adipocytes were
stimulated directly (1 ml of 8–10% (v/v) cells per stimulation) as indicated in the figure legends. After stimula-
tion, cells were washed in KRH buffer without BSA and lysed in lysis buffer. For glucose uptake, freshly isolated
rat adipocytes were washed in glucose-free buffer containing 30 mM HEPES pH 7.4, 120 mM NaCl, 4 mM
KH2OPO4, 1 mM MgSO4, 0.75 mM CaCl2, 10 mM NaHCO3, 200 nM adenosine and 1% (w/v) BSA (incubation
buffer). Adipocyte suspensions (400 ml of 5% (v/v) cells) were pre-incubated with SBI-0206965 or 0.1% DMSO
for 30 min before being stimulated with 10 nM insulin or 10 mM cytochalasin B for 30 min. Subsequently,
100 ml incubation buffer containing 0.25 ml (0.025 mCi) [14C]-glucose (275 mCi/mmol glucose; final glucose
concentration = 0.18 mM) was added and cells were incubated for a further 30 min. Reactions were stopped by
centrifuging 300 ml of each reaction in a Beckman microtube containing 75 ml dinonylphtalate. The adipocyte
fraction was collected and subjected to liquid scintillation counting.
3T3-L1 adipocyte culture and glucose uptake
3T3-L1 fibroblasts were originally obtained from ATCC (#CL-173). The cells were cultured and differentiated
into adipocytes as described previously [47] and used between passages 7 and 12. Experiments were performed
at days 8–12 post differentiation. 2-deoxyglucose uptake assay and preparation of cell lysates were as described
previously [46].
Cell and tissue extract preparation
Treated cells were washed once with PBS and lysed in ice-cold lysis buffer (containing 50 mM Tris–HCl, pH
7.5, 1 mM EGTA, 1 mM EDTA, 270 mM sucrose, 1% Triton X-100, 20 mM glycerol-2-phosphate, 50 mM NaF,
5 mM Na4P2O7, 1 mM DTT, 0.1 mM PMSF, 1 mM benzamidine, 1 μM microcystin-LR, 1 μg/ml leupeptin,
1 μg/ml pepstatin A, and 1 mM Na3VO4). For mouse skeletal muscle tissue samples, ∼10 mg tissue was homo-
genised in 400 μl ice-cold lysis buffer using a Tissuelyser II (Qiagen) at 30 Hz for 30 s (x 2 sets). Cell or tissue
lysates were clarified by centrifugation at 6000×g for 10 min at 4°C, and total protein concentration was deter-
mined using Bradford reagent (#23200, ThermoFisher) and BSA as standard.
Immunoblot analysis
Protein lysates were denatured in Laemmli buffer at 95°C for 5 min. Twenty micrograms of protein was sepa-
rated by SDS–PAGE on home-made Tris-glycine or pre-cast Novex 4–12% Bis-Tris gels (ThermoFisher) and
transferred onto nitrocellulose or Immobilon-FL polyvinylidene difluoride membranes. Membranes were
blocked for 45 min in TBST [Tris-buffered saline (20 mM Tris–HCl, pH 7.6, 137 mM NaCl) with 0.1% Tween
20] containing 5% skimmed milk. Blocked membranes were incubated overnight at 4°C in primary antibody
diluted in TBST containing 4% BSA. Protein detection was performed with horseradish peroxidase-conjugated
secondary antibodies and enhanced chemiluminescence (ECL) substrate or LI-COR IRdye-conjugated second-
ary antibodies and a LI-COR Odyssey infrared imaging system (LI-COR Biosciences). ECL signals were visua-
lised using a ChemiDoc XRS+ system followed by analysis of band intensities with the software Image Lab 6.0
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND).2980





















































































(both from Bio-Rad). LI-COR signals were analysed and quantified using ImageStudioLite software (LI-COR
Biosciences).
Protein expression constructs
AMPKα1 constructs (used in Figure 8) were made by the cloning team at Medical Research Council Protein
Phosphorylation and Ubiquitylation Unit (MRC PPU) Reagents and Services (https://mrcppureagents.dundee.
ac.uk/). The coding region of AMPKα1 (NM_006251.5) was amplified using oligonucleotides adding BglII and
NotI restriction sites at the 50 and 30 end, respectively, and subcloned as a BglII/NotI insert into
pcDNA5D-FRT/TO FLAG vector (DU41457) digested with BamHI and NotI to generate pcDNA5D-FRT/TO
FLAG AMPKα1 (DU67861). The M104T mutant version of this plasmid was made according to the
QuikChange method (Stratagene) using KOD polymerase (Novagen) to generate pcDNA5D-FRT/TO FLAG
AMPKα1 M104T. Plasmid expression constructs for AMPK Flag-α1, β1-Myc, and HA-γ1 (used in Figure 7)
were previously described [32]. Mutagenesis of Flag-α1 was performed as above using the QuikChange
method. Note that the AMPKα1 construct used in Figure 7 is a variant of NM_006251.5 that starts at Met10
(the alternate initiation site), thus the gatekeeper methionine shown as M104 corresponds to M93. Plasmid
constructs for full-length, N-terminal Flag-tagged human ULK1 (NM_003565.4) and the M92T mutant were
generated by custom gene synthesis (Gene Universal) and cloned into pcDNA3.1(−) vector using XhoI/HindIII
restriction sites. All constructs were sequence verified.
Protein production and kinase assays
Heterotrimeric human AMPK Flag-α1β1γ1 and human Flag-ULK1 were produced in mammalian cells as
described [32,35]. For AMPK expression, the cells were triply transfected at 60% confluency using FuGene HD
(Roche Applied Science) and 1 μg of pcDNA3 plasmid expression constructs for AMPK Flag-α1, β1-Myc, and
HA-γ1, whereas for ULK1 expression the cells were transfected with 2 μg of pcDNA3.1(−) Flag-ULK1 plasmid.
After 48 h, the transfected cells were harvested by rinsing with ice-cold PBS, followed by rapid lysis using
500 μl of lysis buffer.
AMPK and ULK1 activity were determined by phosphorylation of synthetic peptide substrates SAMS
(HMRSAMSGLHLVKRR) and S108tide (KLPLTRSHNNFVARRR), respectively [32,35]. Briefly, recombinant
AMPK or ULK1 was immunoprecipitated from 10 μg of transfected cultured cell lysate using 10 μl of
anti-FLAG M2 agarose beads (50% (v/v)) (MerckMilliporeSigma), washed and then added to a 25 μl reaction
containing assay buffer (50 mM HEPES-NaOH, pH 7.4, 1 mM DTT, and 0.02% (v/v) Brij-35), 200 μM syn-
thetic peptide substrate (SAMS or S108tide), 200 μM [γ-32P]-ATP (PerkinElmer), 5 mM MgCl2, in the presence
of Compound C (0–400 μM) or SBI-0206965 (0–400 μM). Reactions were performed at 30°C and terminated
after 10 min by spotting 15 μl onto P81 phosphocellulose paper (Whatman). Radioactivity was quantified by
liquid scintillation counting.
Homogeneous time-resolved fluorescence (HTRF) assay using AMPKα1 and
α2 double KO (DKO) U2OS cells
U2OS FRT Flp-In T-REx cell line was a kind gift from John Rouse (University of Dundee) and dual deletion of
PRKAA1 and PRKAA2 (that encode AMPKα1 and α2, respectively) was performed by Horizon Discovery
using CRISPR–CAS9 technology. HTRF was employed for a higher throughput application, as well as more
sensitive and quantitative detection of ACC phosphorylation (using the phospho-ACC 1/2 (Ser79) kit, #
64ACCPET, Cisbio). Briefly, cells were seeded in a 96-well plate at a density of 5 × 104 cells per well. The next
day, cells were treated with increasing concentration of the indicated compounds diluted in a serum-free
medium. Post-treatment, cells were lysed in 50 μl per well of phospho-total protein lysis buffer 1 (#64KL1FDF,
Cisbio) containing 1 : 100 blocking reagent (#64KB1ACC, Cisbio) with continuous vibration at room tempera-
ture for 30 min. ACC (Ser79) D2- and Cryptate-antibodies were diluted (1 : 40) in the detection buffer. In a
384-well plate, 16 μl lysate and 4 μl antibody solution were added per well. The plate was incubated at room
temperature with light protection. The next day, FRET (665 nm/620 nm) was measured using Spectramax
microplate reader (Molecular Devices) according to the manufacturer instruction.
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Nucleotide and ZMP measurements
Nucleotides and ZMP were measured by liquid chromatography-mass spectrometry from perchlorate extracts
of mouse primary hepatocytes, C2C12 myotubes, and mouse EDL muscle tissues as described previously
[32,45]. Adenylate energy charge was calculated as:
ATPþ 0:5ADPð Þ
ATPþ ADPþ AMPð Þ
Uridine uptake
Uridine uptake assay was performed as described [48]. Briefly, C2C12 myotubes were washed once in uridine
uptake buffer (20 mM Tris–HCl, 3 mM KH2PO4, 1 mM MgCl2, 2 mM CaCl2, 5 mM glucose, 130 mM NaCl,
pH 7.4) before incubating at room temperature in 400 μl uridine uptake buffer containing vehicle (0.1%
DMSO), NBMPR, or SBI-0206965. Thirty minutes following incubation, the buffer was aspirated and the new
400 μl uridine uptake buffer containing the compounds (DMSO, NBMPR, or SBI-0206965) and 0.1 μM (2 μCi/
ml) [3H]-uridine. After 1 min, uridine transport was terminated by washing the cells five times in ice-cold
uridine uptake buffer containing cold 1 mM uridine. The cells were lysed in 200 μl 10% (w/v) SDS before
scraping. The amount of uridine transported into the cells was determined by scintillation counting.
Adenosine kinase assay
Of human recombinant adenosine kinase (BioVision, #8024-AK), 0.5 μg was pre-incubated with non-
nucleoside adenosine kinase inhibitor ABT-702 (Tocris, #2372) or vehicle (DMSO) for 30 min followed by a
further incubation with or without increasing doses (0.1–10 μM) of SBI-0206965 for 60 min. Adenosine kinase
activity was measured using the Universal Kinase Activity kit (R&D System, EA004) using adenosine
(MerckMilliporeSigma, #A9251) as substrate according to the manufacturer protocol.
Protein kinase screen and IC50 determination
All protein kinases in the kinase panel were expressed, purified and assayed at the International Centre for
Protein Kinase Profiling (http:// www.kinase-screen.mrc.ac.uk/), MRCPPU, University of Dundee, as previously
described [30]. Briefly, all assays were carried out at room temperature. Assays were performed for 30 min
(except Lck and PBK that were incubated for 15 min) using Multidrop Micro reagent dispensers (Thermo
Electron Corporation) in a 96-well format. The concentration of magnesium acetate in the assays was 10 mM
and [γ-33P]ATP (∼800 cpm/pmol) was used at either 5, 20, or 50 μM in order to be at or below the Km for
ATP for each enzyme (described under ‘kinase panel’ in the webpage http://www.kinase-screen.mrc.ac.uk/
services/premier-screen). The half-maximal inhibitory concentration (IC50) values of the selected kinases
against SBI-0206965 were performed by the International Centre for Kinase Profiling team and determined
after carrying out assays at ten different concentrations of the compound.
Molecular docking
Molecular docking was performed using the SwissDock server [49] available at http://www.swissdock.ch/ (last
accessed on 20 August 2020). The kinase domain structures of AMPKα2 (PDBid: 6BX6), ULK2 (PDBid:
6YID), MARK3 (PDBid: 2QNJ), MARK4 (PDBid: 5ES1) were prepared for docking using the Chimera plugin
DOCKPREP after removal of water and ligand molecules [50,51]. The ligand SBI-0206965 (ZINC database
entry: 253387916) was docked to each kinase structure using the default settings for ‘accurate’ docking, allowing
flexibility for side chains within 3 Å of any atom of the ligand in its reference binding mode.
Statistical analysis
Results are indicated as means ± standard error mean (SEM). Two-way analysis of variance (ANOVA) with
Tukey’s post hoc analysis was used to determine differences between multiple treatment groups. Significance
was set at P < 0.05.
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SBI-0206965 dose dependently attenuates 991-induced phosphorylation of
ACC and inhibition of lipogenesis in primary hepatocytes
SBI-0206965 was reported to inhibit cellular AMPK activation, assessed by phosphorylation of ACC, at doses
ranging from 5 to 30 μM in multiple cell lines including HEK293, SH-SY5Y, or HUVECs [32,38]. We observed
that SBI-0206965 attenuates basal or 991-stimulated phosphorylation of AMPK substrates (ACC and Raptor)
in a dose-dependent manner in primary mouse hepatocytes (Figure 1A,B). Phosphorylation of AMPKα T172
was modestly elevated with 991, and was further increased with increasing doses of SBI-0206965 (Figure 1A,B).
Since a previous study noted that cellular incubations at high concentrations of SBI-0206965 may induce
AMPKα T172 phosphorylation through fluctuations in AMP/ATP and ADP/ATP ratios [32], we measured the
effect of SBI-0206965 on adenylate energy charge. We indeed observed that SBI-0206965 promoted phosphor-
ylation of AMPKα T172 at higher doses (Supplementary Figure S1A), however, there was no reduction in
adenylate energy charge (Supplementary Figure S1B).
Since activation of AMPK leads to inhibition of lipogenesis through phosphorylation of ACC1 in hepatocytes
[6,7,42], we tested if SBI-0206965 treatment could prevent 991-induced suppression of lipogenesis. As previ-
ously reported [7,27], 991 potently inhibited lipogenesis in hepatocytes (Figure 1C). Co-treatment with
SBI-0206965 attenuated 991-induced inhibition of lipogenesis in a dose-dependent manner. When co-treated
with a 25 μM dose of SBI-0206965, the inhibitory effect of 991 was fully restored to the level comparable to the
vehicle-treated state (Figure 1C). As shown in Figure 1D, we observed an inverse relationship between ACC
phosphorylation and lipogenesis in response to increasing doses of SBI-0206965 with 991 (10 μM). These
results demonstrate that SBI-0206965 is a useful tool compound to probe AMPK-dependent regulation of lipo-
genesis by small-molecule activators in primary hepatocytes.
SBI-0206965 potently inhibits glucose uptake in C2C12 myotubes and
adipocytes
We next assessed the effects of SBI-0206965 on AMPK signalling and glucose uptake in C2C12 myotubes.
SBI-0206965 (10 μM) alone modestly increased phosphorylation of AMPKα with no apparent effect on phos-
phorylation of AMPK substrates (ACC, Raptor, TBC1D1, ULK1) (Figure 2A,B and Supplementary
Figure S1A). As anticipated, 991 (10 μM) enhanced phosphorylation of AMPK substrates to varying degrees.
Treatment of C2C12 myotubes with increasing doses of SBI-0206965 in combination with 991 resulted in a
dose-dependent decrease in Raptor phosphorylation, however, phosphorylation of ACC and ULK1 was only
modestly decreased at doses up to 50 μM (Figure 2A,B). Notably, phosphorylation of TBC1D1, known to be
involved in AMPK-mediated glucose uptake in skeletal muscle [9–11], was unchanged with SBI-0206965
(Figure 2A,B). In contrast, phosphorylation of extracellular signal-regulated kinase (ERK), used as control unre-
lated to AMPK signalling, was markedly inhibited with SBI-0206965 at 5 μM (Figure 2A). SBI-0206965
(10 μM) suppressed basal glucose uptake by more than 50%, whereas 991 stimulated glucose uptake by ∼2-fold
and this was dose dependently reduced with SBI-0206965 (Figure 2C). Even though 5 μM SBI-0206965 had no
apparent inhibitory effect on phosphorylation of AMPK substrates (Figure 2A,B), it was sufficient to fully
inhibit 991-stimulated glucose uptake in C2C12 myotubes (Figure 2C). Contrary to the inhibitory effect of
SBI-0206965 on phosphorylation of AMPK substrates, 991-stimulated phosphorylation of AMPKα T172 was
further elevated with increasing doses of SBI-0206965 (Figure 2A). Consistent with the observation in hepato-
cytes (Supplementary Figure S1A) SBI-0206965 dose dependently promoted phosphorylation of AMPKα and
there was no change in adenylate energy charge (Supplementary Figure 1C,D). Collectively, SBI-0206965 is a
potent inhibitor for basal and 991-stimulated glucose uptake, although it promotes phosphorylation of
AMPKα T172 and has only a modest inhibitory effect on phosphorylation of AMPK substrates in C2C12
myotubes.
Since we observed that SBI-0206965 potently inhibits basal and 991-stimulated glucose uptake with no
detectable inhibition of TBC1D1 phosphorylation, we tested if SBI-0206965 suppresses insulin-stimulated (i.e.
AMPK-independent) glucose uptake in C2C12 myotubes. SBI-0206965 doses ≥25 μM consistently inhibited
insulin-stimulated phosphorylation of Akt and its downstream targets including AS160 (also known as
TBC1D4), which plays a key role in regulating GLUT4 trafficking [11,52,53] (Figure 3A,B). We observed that
basal and insulin-stimulated glucose uptake were robustly inhibited with SBI-0206965 (Figure 3C), which is
consistent with a previous study using L6 myotubes and isolated mouse skeletal muscle ex vivo [54].
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND). 2983

























































































Figure 1. SBI-0206965 dose dependently attenuates 991-induced phosphorylation of ACC and inhibition of lipogenesis in mouse primary
hepatocytes. Part 1 of 2
(A,B) Mouse primary hepatocytes were pre-incubated for 30 min with vehicle (0.1% DMSO) or the indicated concentrations of SBI-0206965 followed
by an additional incubation for 1 h with 991 (10 μM) or vehicle. Cell lysates were subjected to immunoblot analysis using the indicated antibodies.
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND).2984





















































































Figure 1. SBI-0206965 dose dependently attenuates 991-induced phosphorylation of ACC and inhibition of lipogenesis
in mouse primary hepatocytes. Part 2 of 2
Tubulin was used as a loading control. Representative images (A) and quantification of the indicated blots (B) from three
independent experiments are shown (n = 6 per treatment). (C) Mouse hepatocytes were treated with the indicated
concentrations of SBI-0206965 in the absence (vehicle) or presence of 991 (10 μM) and labelled with [14C]-acetate for 3 h.
Rates of fatty acid synthesis were estimated from incorporation [14C]-acetate into saponifiable lipids. (D) Results from (B) and
(C) (except vehicle and SBI-0206965 alone data) are plotted to visualise the inverse relationship between ACC phosphorylation
and lipogenesis in response to increasing doses of SBI-0206965 in combination with 991 (10 μM). Results are expressed as
percentage relative to the vehicle and represent the mean ± SEM for three independent experiments (n = 6–12 per treatment).
*P < 0.05 (vehicle vs. indicated compound(s) treated). N.S.; not significant.
A B
C
Figure 2. SBI-0206965 inhibits unstimulated and 991-stimulated glucose uptake with no apparent inhibition of TBC1D1 Ser231
phosphorylation in C2C12 myotubes.
(A,B) C2C12 myotubes were pre-incubated for 30 min with vehicle (0.1% DMSO) or the indicated concentrations of SBI-0206965 followed by an
additional 1 h incubation with 991 (10 μM) or vehicle. Cell lysates were subjected to immunoblot analysis using the indicated antibodies. Tubulin
was used as a loading control. Representative images (A) and quantification of the indicated blots (B) from three independent experiments are
shown (n = 3 per treatment). (C) C2C12 myotubes were incubated with vehicle or the indicated compounds for 1 h followed by addition of
[3H]-2-deoxy-glucose and measurement of glucose uptake for 5 min (n = 8–9 per treatment). Results are expressed as mean ± SEM. *P < 0.05
(vehicle vs. indicated compound(s) treated).
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Collectively, these results demonstrate that SBI-0206965 potently inhibits insulin-stimulated glucose uptake and
modestly inhibits insulin signalling intermediaries in C2C12 myotubes.
To further examine if SBI-0206965 ubiquitously inhibits the glucose transport system in different cell types,
we also treated rat primary adipocytes with SBI-0206965 in the presence or absence of insulin. Consistent with
our observation in C2C12 myotubes, both basal and insulin-stimulated glucose uptake were dose dependently
reduced in primary adipocytes (Figure 3D). However, contrary to the inhibitory effect on insulin signalling
intermediaries in C2C12 myotubes (Figure 3A,B), SBI-0206965 had no effect on phosphorylation of Akt and
its substrates (AS160 and GSK3α/β) in primary adipocytes (Figure 3E). We also assessed the effect of
SBI-0206965 on 991-induced AMPK activation in primary adipocytes and observed that phosphorylation of
Raptor, but not ACC, was only modestly reduced at 50 or 100 μM (Supplementary Figure S2A,B). We also
used 3T3 L1 mouse adipocytes and observed that SBI-0206965 (30 μM) profoundly inhibited both basal and
insulin-stimulated glucose uptake (Supplementary Figure S2C). Taken together, SBI-0206965 inhibits both sti-
mulated and unstimulated glucose transport in multiple cell types.
SBI-0206965 inhibits the nucleoside transport system
AICAR is the most widely used compound to pharmacologically activate AMPK and probe AMPK’s cellular
and physiological functions, although its specificity has recently been challenged [20–22]. Upon uptake into
cells, AICAR is converted to the monophosphate derivative, ZMP, which can accumulate to high levels, and
mimics the effects of AMP on the AMPK pathway. Consistent with previous findings using HEK293 cells [32],
we observed that SBI-0206965 potently inhibits AICAR uptake (measured as cellular ZMP accumulation) in
both C2C12 myotubes and isolated mouse skeletal muscle (EDL) tissue ex vivo (Figure 4A,B). To determine if
the reduced accumulation of ZMP was due to inhibition of the transport or conversion of AICAR to ZMP
through phosphorylation by adenosine kinase, we measured the effect of SBI-0206965 on the activity of human
recombinant adenosine kinase in vitro. We observed that while a non-nucleoside adenosine kinase inhibitor





Figure 3. SBI-0206965 inhibits insulin-stimulated glucose uptake in C2C12 myotubes and rat primary adipocytes.
(A,B) C2C12 myotubes were pre-incubated for 30 min with vehicle (0.1% DMSO) or the indicated concentrations of SBI-0206965 followed by an
additional incubation without (vehicle) or with insulin (100 nM) for 1 h. Cell lysates were subjected to immunoblot analysis using the indicated
antibodies. Tubulin was used as a loading control. Representative images (A) and quantification of the indicated blots (B) from three independent
experiments are shown (n = 3 per treatment). (C) C2C12 myotubes were incubated with vehicle or the indicated compounds for 1 h followed by
addition of [3H]-2-deoxy-glucose and measurement of glucose uptake for 5 min (n = 6 per treatment). (D,E) Rat primary adipocytes were
pre-incubated with vehicle (0.1% DMSO) or the indicated concentrations of SBI-0206965 for 30 min before being stimulated with insulin (10 nM) for
30 min. The adipocytes were either lysed for immunoblot analysis (E, n = 4 per treatment) or incubated further 30 min with an addition of
[14C]-glucose for determination of glucose uptake (D, n = 4 per treatment). Results are expressed as mean ± SEM. *P < 0.05 (vehicle vs. indicated
compound(s) treated).
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kinase up to 10 μM (Supplementary Figure S3). In line with these observations, SBI-0206965 also inhibited the
uptake of uridine (ribonucleoside), although the potency was much more modest compared with NBMPR, a
known inhibitor of nucleoside transporters [55] (Figure 4C). These results, together with a previous report
[32], establish that SBI-0206965 inhibits the nucleoside transport system when used at ≥5–10 μM in multiple
cell types and skeletal muscle tissue.
In vitro screen of SBI-0206965 against an extended panel of human protein
kinases
Given the similarity of the kinase domain structure between AMPK and AMPK-related kinases (BRSK1,
BRSK2, MARK1, MARK2, MARK3, MARK4, MELK, NUAK1, NUAK2, SIK1, SIK2, SIK3, SNRK) [40,41], we
hypothesised that SBI-0206965 also inhibits several members of the AMPK-related kinases. In a previous study
[32], among 13 members of the AMPK-related kinases only MARK3 was included in the screen. Notably,
while AMPK was most potently inhibited (∼80%) by SBI-0206965 (used at 0.25 μM), cross-reactivity with
MARK3 (>40% inhibition) was also observed [32]. To gain a better understanding of SBI-0206965 selectivity
we performed a screen against an expanded kinase panel consisting of 140 kinases, 49 of which overlap with a
previous report [32]. Importantly, our panel includes 10 members of the AMPK-related kinases (BRSK1,
BRSK2, MARK1, MARK2, MARK3, MARK4, MELK, NUAK1, SIK2, SIK3). Our results were similar to the
results obtained in the previous screen [32] and SBI-0206965 robustly inhibited AMPK (∼80%) and to a lesser
degree (∼30–50% inhibition) multiple other kinases (e.g. MARK3, MLK3, PAK4, Src, TrkA) (Figure 5A).
Interestingly, our expanded screen revealed that SBI-0206965 also inhibits MLK1 and NUAK1 more potently
than AMPK and ULK1/2, while an additional 25 kinases were inhibited by ≥25% (Figure 5B,C). We next deter-
mined the half-maximal inhibitory concentration (IC50) of SBI-0206965 against AMPK and MLK1, as well as
selected AMPK-related kinases (MARK3/4, NUAK1, SIK2). In line with the results of our single concentration
screen (Figure 5C), we observed that IC50 values (ATP concentration = 20 μM) for MLK1 (0.071 μM) and
NUAK1 (0.087 μM) were noticeably lower than AMPK (0.170 μM) (Figure 5D).
SBI-0206965 inhibits kinases that contain methionine at the gatekeeper
residue
Structures of SBI-0206965 (Figure 6A) bound to AMPKα2 and ULK2 kinase domains have provided a detailed
view of how this inhibitor engages the ATP-binding cleft of protein kinases (Figure 6B). Both structures
revealed a compound binding mode that is characteristic of type I kinase inhibitors, taking advantage of the
‘active-like’ conformation of the kinase domain. SBI-0206965 engages the hinge region, the canonical DFG
A B C
Figure 4. SBI-0206965 inhibits AICAR and uridine uptake in C2C12 myotubes.
(A,B) C2C12 myotubes or isolated mouse skeletal muscle (extensor digitorum longus) were pre-incubated for 30 min with vehicle (0.1% DMSO) or
the indicated concentrations of SBI-0206965 followed by an additional 1-h incubation without (vehicle) or with AICAR (1 mM). Cell or tissue extracts
were subjected to ZMP analysis by liquid chromatography-mass spectrometry. (C) C2C12 myotubes were incubated in the absence (vehicle) or
presence of the indicated compounds for 30 min followed by an addition of [3H]-uridine for 1 min for determination of uridine uptake. Results are
expressed as mean ± SEM. *P < 0.05 (AICAR (A,B) or vehicle (C) vs. SBI-0206965 or NBMPR). N.D.; not detectable.
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Figure 5. Kinase selectivity profile for SBI-0206965. Part 1 of 2
(A–C) A screen of 140 human protein kinases (n = 2 per kinase, with or without 1 μM SBI-0206965) was performed in vitro
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motif and, importantly, the bromine atom fills the ‘back pocket’ next to the methionine ‘gatekeeper’ residue
(Figure 6B). To gain a general overview of how SBI-0206965 may be interacting with MARK3 and MARK4 we
performed molecular docking experiments using the SwissDock server [49]. As expected, SBI-0206965 engages
MARK3 and MARK4 in a similar manner as AMPKα2 and ULK2 and binds in the ATP cleft with the
bromine atom facing the methionine gatekeeper residue (Figure 6B). The position of docked SBI-0206965 was
Figure 5. Kinase selectivity profile for SBI-0206965. Part 2 of 2
using the MRC-PPU Premier Screen service as described in Materials and methods. Results from the current profiling (140
kinases) were shown as; kinases profiled previously (49 kinases) by Dite et al. [32] (A) or not profiled (91 kinases) (B) or
combined data from A and B (C). (D) The half-maximal inhibitory concentration (IC50) values of the selected kinases against
SBI-0206965 were performed using the indicated concentrations of ATP. Results are expressed as mean ± SEM.
A B
C
Figure 6. SBI-0206965 inhibitor engagement with kinase ATP-binding clefts.
(A) Chemical structure of SBI-0206965. (B) Kinase domain structures with bound and/or docked SBI-0206965 in the active site. SBI-0206965
engages the ATP-binding cleft near the hinge region and gatekeeper residue. Docked compound structures are shown in grey with coloured
heteroatoms (red, oxygen; blue, nitrogen). Accession PDBid codes for bound compound structures: 6BX6, AMPKα2; 6YID, ULK2. (C) Gatekeeper
residues of AMPK-related kinases (top panel) and a select set of kinases sensitive to SBI-0206965 (middle panel). Gatekeeper residues of ULK3
and ULK4 are shown (bottom panel).
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND). 2989





















































































almost identical with the position of the bound compound to AMPKα2 and ULK2 (Figure 6B), thus validating
our molecular docking approach for determining the general binding mode of SBI-0206965 to MARK3 and
MARK4. Interestingly, we noticed that most SBI-0206965-sensitive kinases contain a large gatekeeper residue
and a preference for methionine at this position (Figure 6C, Supplementary Figure S4).
Mutation of the gatekeeper methionine to threonine renders AMPK and ULK1
resistant to SBI-0206965 in vitro
We wondered if converting the gatekeeper residue methionine to an amino acid with a smaller side chain (e.g.
threonine) would lead to loss of SBI-0206965 inhibition. We mutated the gatekeeper residue of AMPKα1
(M104→ Thr; M104T) or ULK1 (M92T) and expressed the respective mutant or wild type (WT) in mamma-
lian cells. Immunoblot analysis showed that levels of total (AMPKα1 and ULK1) and AMPK α1-pThr172 were
comparable between WT and the respective gatekeeper mutant (Figure 7A,B). We observed that both AMPKα1
M104T and ULK1 M92T mutants had lower activity in vitro compared with respective WT forms (Figure 7C,
D). Despite the reduced basal activity, AMPKα1 M93T mutant was equally responsive to allosteric AMPK acti-
vators AMP and A-769662 (that bind the nucleotide-binding domain of γ subunit and ADaM site located at
the interface of the α and β subunit, respectively [3]) compared with WT (Figure 7E,F). Notably, we observed a
marked increase in SBI-0206965 IC50 for AMPKα1 M104T (∼20 fold) and ULK1 M92T (∼7-fold) compared
with their respective WT control suggesting the importance of a methionine gatekeeper for SBI-0206965 inhib-
ition. In contrast, the IC50 was virtually unchanged (within 2-fold difference) when Compound C, an
ATP-competitive inhibitor that binds to the highly conserved active site of AMPK [29], was tested for inhib-
ition of AMPK and ULK1 WT and mutant forms (Figure 7G–J).
Mutation of the gatekeeper methionine to threonine renders AMPK resistant
to SBI-0206965 in cells
We next wanted to verify if in vitro results of the SBI-0206965-insensitive AMPK mutant (Figure 7G,H) can be
recapitulated in a cellular context. We generated AMPKα1/α2 double knockout (DKO) U2OS cells
(Supplementary Figure S5) and transfected the DKO cells with AMPKα1 WT or M104T mutant, which allowed
us to avoid the influence of endogenous AMPKα in the mutant-expressing cells. The transfected cells were
treated with vehicle or SBI-0206965 followed by incubation with vehicle or 991. Using a sensitive and quantita-
tive HTRF assay, phosphorylation of ACC (Ser79) was measured as surrogate readout of cellular AMPK activity.
As shown in Figure 8A, 991 equally increased ACC phosphorylation ∼2.5-fold in AMPKα1 WT- and
M104T-expressing cells. Consistent with in vitro kinase activity data, the inhibitory effect of SBI-0206965 on
ACC phosphorylation was blunted in AMPKα1 M104T-expressing cells compared with WT-expressing cells
(Figure 8B). In contrast, the inhibitory effect of Compound C on ACC phosphorylation was similar between
WT- and M104T-expressing cells (Figure 8C). Immunoblot analysis confirmed differential effects of
SBI-0206965 on ACC phosphorylation (measured by HTRF assay, Figure 8A, B) in WT- and M104T-expressing
cells and also consistent/comparable expression of the transfected WT and M104T mutant (Figure 8D).
Collectively, we demonstrate the key role of a methionine gatekeeper for SBI-0206965-mediated inhibition of
AMPK and have designed an inhibitor-insensitive mutant form of AMPK that can be used as control.
Discussion
The use of protein kinase inhibitors as tool compounds have transformed our ability to study cell signalling
and resulting biological responses. However, for chemical probes to be useful a thorough analysis of their off-
target effects is paramount. We have demonstrated that SBI-0206965 is not a highly selective inhibitor for
either ULK1 or AMPK. In cell-free assays, SBI-0206965 inhibits MLK1/3, NUAK1 and also FAK [34] at the
same levels as, or more robustly than ULK1 or AMPK. We also show that in intact cells, SBI-0206965 potently
inhibits glucose and nucleoside uptake independent of its inhibition of AMPK activity. Analysis of co-crystal
structures of AMPK-SBI-0206965 or ULK2-SBI-0206965 complex and computational modelling has revealed
the importance of the gatekeeper methionine as a key determinant of SBI-0206965 sensitivity.
A previous study reported superior selectivity and preferable characteristics of SBI-0206965 for AMPK rela-
tive to Compound C, and a co-crystal structure of the AMPKα2 kinase domain (residues 6–278)-SBI-0206965
complex showed that the drug occupies a pocket that partially overlaps with the ATP-binding site [32]. The
ATP-binding site is composed of the adenine pocket (near the hinge region), the ribose-interacting region, the
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND).2990





























































































Figure 7. Mutation of gatekeeper methionine to threonine renders AMPK and ULK1 insensitive to SBI-0206965 in
cell-free assay. Part 1 of 2
(A–J) Immunopurified recombinant Flag-AMPKα1 (wild type (WT), M104T) complex or Flag-ULK1 (WT, M92T mutant) were
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND). 2991





















































































phosphate-coordinating region, the solvent accessible region, and the buried region [56,57]. The size and shape
of the buried region is controlled by the gatekeeper residue, which serves as a molecular gate controlling the
accessibility to this pocket and the nature of interactions with ligands (as seen in Figure 6C) [57,58]. In ∼73%
of human kinases, a hydrophobic amino acid with a bulky side chain (Met, Phe, or Leu) is observed at that
position, 22% have a small residue, such as Thr or Val and the remaining 5% have one of the remaining amino
acids [57]. It has been reported that the amino acid distribution of the gatekeeper residue in some of the kinase
groups differ significantly from the whole distribution. In particular, methionine is relatively more frequent
(∼20 kinases) in the tyrosine kinase group than in the overall distribution [59]. We noticed that among the top
30 kinases inhibited by SBI-0206965 (>25% inhibition, Figure 5C) in the current screen, 25 kinases have
medium (Met, Leu) or large gatekeepers (Phe, Tyr) and the other 4 kinases (YES, SRC, DDR2, TIE2, FGFR1)
have a small gatekeeper (Thr, Ile, Val) (Supplementary Figure S4A). Notably, 19 out of 30 kinases (MLK1,
NUAK1, ULK1, AMPK, MLK3, ULK2, Aurora B, PAK4, MARK4, MST3, MARK3, MAP4K5, GCK, IGF-1R,
MARK1, MST2, MARK2, MARK2, JAK3, IRR, TAK1) have methionine in their gatekeeper residue. Consistent
with this, out of the top 18 kinases whose binding/activity was shown to be inhibited by SBI-0206965 [34],
seven of them (ULK1, ULK2, FAK, JAK3, JAK2, NUAK2, PAK1) have methionine in their gatekeeper residue.
Nonetheless, it should also be noted that there are kinases with a methionine gatekeeper residue (e.g. JNKs),
which are not selectively inhibited by SBI-0206965 [31,33].
We show here that converting the gatekeeper residue methionine of AMPKα1 (M104) or ULK1 (M92) to an
amino acid with a smaller side chain (Thr) attenuated SBI-0206965 inhibition in a cell-free assay. Importantly,
reintroducing WT or the M104T mutant of AMPKα1 into AMPKα1/α2 DKO U2O2 cells shows that the gate-
keeper residue is also critical for efficient AMPK inhibition in cellulo. Interestingly, we observed that
Compound C was not affected by mutations of the gatekeeper residue in AMPK and ULK1 in vitro or AMPK
in cellulo. Structures of the AMPKα2 kinase domain bound to SBI-0206965 [32] and Compound C [29] show
that SBI-0206965 contacts mainly the ATP pocket, hinge region and the gatekeeper region. In addition to the
hinge and gatekeeper regions, Compound C interacts with the C-lobe αD helix and the activation segment,
which has moved within the ATP-binding grove (Supplementary Figure S6). Therefore, Compound C is likely
to be less reliant on interactions with the gatekeeper residue than SBI-0206965.
We and others [32,34] have observed that SBI-0206965 doses ≥25 μM increase phosphorylation of AMPKα
T172 in multiple cell types, which may be due to off-target effects or cellular toxicity by reduced cellular
adenylate energy charge as there was a trend toward reduced adenylate energy charge at 30 μM [32]. Contrary
to this hypothesis, we did not observe reduced AMP/ATP, ADP/ATP ratio or adenylate energy charge in both
C2C12 and primary hepatocytes with SBI-0206965 (up to 50 μM). We show that SBI-0206965 does not activate
(>25%) upstream kinases (LKB1 or CaMKK2) that catalyse AMPKα T172 in the cell-free assay (Figure 5). It is
unknown if SBI-0206965 inhibits a protein phosphatase that regulates AMPKα T172 or if inhibitor binding
causes a conformational change that makes T172 less accessible to a phosphatase. Nonetheless, we observed
that SBI-0206965-induced phosphorylation of AMPKα T172 was not accompanied by an increase but rather a
decrease in AMPK substrate phosphorylation. This is presumably because SBI-0206965 binds the kinase
domain and inhibits the catalytic activity of AMPK [32], negating the effect of increases in AMPKα T172 phos-
phorylation. This highlights the unreliability of using AMPKα T172 phosphorylation as a sole readout of cellu-
lar AMPK activity. In mouse embryonic fibroblasts (MEFs) and HEK293 cells, SBI-0206965 treatment at 10–
50 μM (1 h) appeared to cause reduced activity of FAK, while mTOR, Akt, or ERK signalling were unaltered
[34]. We observed that in C2C12 myotubes, but not adipocytes, Akt and ERK signalling were inhibited with
≥25 μM SBI-0206965.
In previous studies, SBI-0206965 was used to probe the effect of AMPK activators on glucose uptake in iso-
lated rodent skeletal muscle ex vivo. It was reported that AICAR-mediated increase in phosphorylation of
AMPK substrates (ACC, ULK1, or TBC1D1) was reduced with SBI-0206965 (used at 10 or 100 μM), which
was accompanied by a profound reduction in glucose uptake in isolated rodent skeletal muscle ex vivo [54,60].
However, the results of these studies need to be cautiously interpreted as SBI-0206965 potently inhibits cellular
Figure 7. Mutation of gatekeeper methionine to threonine renders AMPK and ULK1 insensitive to SBI-0206965 in
cell-free assay. Part 2 of 2
subjected to immunoblot analysis with the indicated antibodies (A,B) or in vitro kinase assay without (C,D) or with the indicated
compounds (E–J). Results are expressed as mean ± SEM.
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uptake of AICAR (i.e. cellular accumulation of ZMP) at 10 μM in cultured cells and intact skeletal muscle
tissue ([32] and the current study), and the above studies [54,60] did not report muscular ZMP content with




Figure 8. Mutation of gatekeeper methionine to threonine renders AMPK insensitive to SBI-0206965 in cells.
(A–D) cDNA constructs encoding Flag-AMPKα1 wild type (WT) or M104T mutant were transfected into AMPKα1/α2 double knockout (DKO) U2OS
cells in 96-well plate. Forty-eight hours post transfection, cells were treated with indicated compounds for 1 h prior to cell lysis. Cell lysates were
subjected to homogeneous time-resolved fluorescence (HTRF) assay, as described in the Materials and methods section, or immunoblot analysis.
(A) Phosphorylation of ACC with vehicle (0.1% DMSO) or 991 (10 μM) using HTRF assay. Data are shown as % of 991-stimulated (100%) state. (B,
C) % ACC phosphorylation (HTRF assay) relative to respective 991-stimulated value (100%) in response to increasing doses of SBI-0206965 or
Compound C. (D) Immunoblot analysis of lysates from Flag-AMPKα1 WT (upper panel) or M104T mutant (lower panel) expressing cells using the
indicated antibodies. Results are from three independent experiments (n = 6–9 per treatment) and are expressed as mean ± SEM.
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND). 2993





















































































competition for adenosine transporter binding sites, which accounts for its inhibitory effects on
AICAR-mediated AMPK activation [61]. Based on the results reported in the previous [32,61] and the current
study, we would strongly advise against the use of SBI-0206965 or Compound C in combination with AICAR
when investigating cellular AMPK signalling and function.
A recent study reported that SBI-0206965 inhibits unstimulated and insulin-stimulated glucose transport in
isolated skeletal muscle tissue and cultured L6 myotubes without apparent effect on GLUT4 translocation in L6
muscle cells [54]. This is reminiscent of the p38 MAPK inhibitor SB-203580, which was shown to inhibit
insulin-stimulated glucose transport in skeletal muscle tissue/cells and adipocytes [62]. Using a
SB-203580-resistant mutant of p38 MAPK, it was unambiguously shown that the inhibitory effect of
SB-203580 on glucose transport was independent of p38 MAPK [63]. Along the same lines, it would be useful
to utilise SBI-0206965-resistant mutant AMPK or ULK1 to probe drug selectivity towards respective kinase sig-
nalling pathways. For this purpose, we generated AMPKα1α2 DKO U2OS cells and transfected the DKO cells
with AMPKα1 WT or M104T mutant, which allowed us to avoid the effect of SBI-0206965 on endogenous
AMPKα in the mutant-expressing cells. A similar approach may be needed for the ULK pathway (e.g. use of
ULK1/2 DKO cells and introduction of WT or M92T mutant). It would also be interesting to assess if the
SBI-0206965-resistant mutant can be exploited to delineate drug selectivity towards the functional/physiological
outputs of the kinases. However, it might be technically challenging since the SBI-0206965-resistant mutants
display only a partial resistance to the inhibitor action.
In conclusion, while SBI-0206965 was reported as a highly selective inhibitor against ULK1 [34] and AMPK
[32], we and others demonstrate that in vitro the compound is a potent inhibitor of several other kinases,
including NUAK1, FAK, MLK1/3, and MARK3/4, all of which contain a methionine in their gatekeeper pos-
ition. In addition to these kinases, SBI-0206965 also inhibits glucose and nucleoside transport systems; there-
fore, the drug effect on cell growth, metabolism or survival needs to be carefully assessed not only when
studying kinase signalling cascades, but also when investigating nutrient and metabolite levels. Considering the
cross-talk in kinase signalling networks and the myriad of roles that AMPK has in regulating metabolism, the
field is still in need of a more selective and potent tool compound. Until more specific AMPK inhibitors are
discovered, cautious use of the current tools and careful interpretations of results are advised. Our study has
revealed inhibitor-insensitive mutant forms of AMPK and ULK1 that could be exploited as potential controls.
We hope that our conclusions stimulate a search for better tool compounds and improved experimental design
to probe AMPK and ULK1/2 functions.
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